Explore our strategy and projects
to learn about the future of our company
Results FY 2023 (€/MLN)
1,148
Revenues
375
Adjusted EBITDA
224
Adjusted net profit
209
Free cash flow
![Calendar](/sites/default/files/styles/image_medium/public/2023-09/Investors_calendar.jpg?itok=yimNErm9)
LIAISON PLEX® System: the new multiplexing platform of the Group
Diasorin's LIAISON PLEX® System and Respiratory Flex Assay Revolutionize Diagnostics with Flexibility and have Earned FDA Clearance.
![Liaison Plex](/sites/default/files/styles/image_medium/public/2024-04/_R6_2677-Migliorato-NR-20240408-084211.jpg?itok=HR4JmKoy)
Keep
in touch
Sign up for our investor alerts
and stay informed
on the latest developments